VALION BIO REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS
Valion Bio reported Q1 2026 results with a net loss of $6.2 million ($2.23 per share), widening from a $1.5 million loss in the prior year quarter. The increase in losses is attributed to the integration of its newly acquired subsidiary, Velocity Bioworks, and one-time costs associated with its corporate rebranding from Tivic Health Systems. Operating expenses rose to $5.6 million from $1.4 million year-over-year, driven by higher R&D and SG&A costs. The company ended the quarter with $7.2 million in cash, down from $12.6 million at year-end, and stated it is evaluating capital alternatives to support future pipeline and manufacturing milestones.
Key figures
- Revenue
- 0
- Net loss
- 6202000
- Sga expenses
- 3780000
- R and d expenses
- 1854000
- Operating expenses
- 5634000
- Weighted avg shares
- 2883650
- Cash and equivalents
- 7215000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.